CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The Company is developing a novel class of investigational antibody therapeutics, based on its Probody® technology platform, for the treatment of cancer. The technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. Together with the Company’s partners, CytomX has advanced five drug-candidates into clinical trials, three of which are in Phase 2 studies and two of which are in Phase 1 studies. The Company’s lead product candidate (CX-2009) is a CD166-targeting Probody drug conjugate wholly-owned by CytomX (CX-2009), currently in Phase 2 clinical trials. The Company is also developing a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029), also currently in Phase 2 clinical trials.